Login to Your Account

Pharma: Clinic roundup

Wednesday, May 14, 2014
Astrazeneca plc, of London, reported phase III data showing that the combination of saxagliptin/dapagliflozin, as a dual add-on therapy in adults with type 2 diabetes who were inadequately controlled on metformin, resulted in statistically significant reductions in HbA1c with the combination vs. either agent alone.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription